15 completed, 8 recruiting, 7 terminated, 6 active not recruiting. 26 Phase 1, 22 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Completed 10, Active not recruiting 4, Terminated 4, Withdrawn 4, Recruiting 3, Unknown 1 |
| Phase 2 | 22 | Completed 11, Recruiting 5, Active not recruiting 3, Terminated 3 |
Follow Refractory Small Lymphocytic Lymphoma: new trials by email Literature Review of Refractory Small Lymphocytic Lymphoma trials Research Report on Refractory Small Lymphocytic Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-05-27 | 2026-10-06 |
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2025-06-02 | 2026-04-22 |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy - B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 27 | 2024-03-18 | 2026-02-13 |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies BGB-21447 - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 | Terminated | BeOne Medicines | 51 | 2023-06-20 | 2026-07-14 |
| Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial Acalabrutinib, Venetoclax, Biospecimen Collection - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2023-05-31 | 2026-05-18 |
| CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563, Bendamustine, Biospecimen Collection - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Recruiting | Mayo Clinic | 25 | 2022-10-03 | 2026-06-09 |
| Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation Ibrutinib, Ipilimumab, Nivolumab - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2022-07-14 | 2025-02-28 | |
| CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL CpG-STAT3 siRNA CAS3/SS3, Radiation Therapy - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2021-07-27 | 2024-04-25 | |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2021-01-25 | 2026-05-29 |
| Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study Daratumumab, Ibrutinib - Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Terminated | Mayo Clinic | 8 | 2020-11-11 | 2025-12-30 |
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL Dose combination 1-1, dose combination 1-2, Dose combination 1-3 - Chronic Lymphocytic Leukemia, CLL | Phase 1 | Withdrawn | Virginia Commonwealth University | 2020-10-02 | 2021-11-09 | |
| Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Acalabrutinib, Obinutuzumab, Venetoclax - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 168 | 2020-07-29 | 2026-09-10 |
| CD19-Specific T Cells Post AlloSCT Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine - B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 4 | 2020-06-26 | 2021-06-02 |
| Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Duvelisib - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 15 | 2020-05-13 | 2026-01-05 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - CD19 Positive, CD20 Positive | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 24 | 2019-10-04 | 2026-08-20 |
| Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor Trabectedin, Venetoclax - Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2019-06-18 | 2023-09-25 |
Showing 20 of 41. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (41) · Lymphoma, Follicular (16) · Lymphoma, Mantle-Cell (16) · Lymphoma, B-Cell, Marginal Zone (15) · Lymphoma, Large B-Cell, Diffuse (11) · Lymphoma, Non-Hodgkin (11) · Lymphoma, B-Cell (8) · Hodgkin Disease (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia, Myeloid, Acute (5) · Myelodysplastic Syndromes (5) · Waldenstrom Macroglobulinemia (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Leukemia, Prolymphocytic, B-Cell (4) · Multiple Myeloma (4)
Chronic Disease (41) · Disease Attributes (41) · Hematologic Diseases (41) · Hemic and Lymphatic Diseases (41) · Immune System Diseases (41) · Immunoproliferative Disorders (41) · Leukemia (41) · Leukemia, B-Cell (41) · Lymphatic Diseases (41) · Lymphoproliferative Disorders (41) · Neoplasms (41) · Neoplasms by Histologic Type (41) · Pathologic Processes (41) · Pathological Conditions, Signs and Symptoms (41) · Leukemia, Lymphoid (40)
Cyclophosphamide (11) · ibrutinib (10) · Lenalidomide (7) · Specimen Handling (7) · fludarabine phosphate (7) · venetoclax (7) · Biopsy (6) · Magnetic Resonance Spectroscopy (6) · Mycophenolic Acid (6) · Rituximab (6) · Whole-Body Irradiation (6) · CT-P10 (5) · obinutuzumab (5) · fludarabine (4) · Cyclosporine (3)
Fred Hutchinson Cancer Center (9) · M.D. Anderson Cancer Center (9) · Mayo Clinic (6) · National Cancer Institute (NCI) (5) · City of Hope Medical Center (3) · Academic and Community Cancer Research United (1) · Alexey Danilov, MD (1) · BeOne Medicines (1) · Emory University (1) · Jonsson Comprehensive Cancer Center (1) · Joseph Tuscano (1) · OHSU Knight Cancer Institute (1) · Steven E. Coutre (1) · Virginia Commonwealth University (1)
United States (38) · Australia (1) · China (1) · Germany (1) · New Zealand (1)
Joseph M Tuscano (2) · Mazyar Shadman (2) · Nitin Jain (2) · William G Wierda (2) · Alessandra Ferrajoli (1) · Alexey Danilov (1) · Alexey V Danilov (1) · Brenda Sandmaier (1) · Catherine S Diefenbach (1) · Chitra Hosing (1) · Craig Okada, M.D. (1) · Daniel A Pollyea (1) · David Maloney (1) · Jennifer R Brown (1) · Jithma P. Abeykoon, MD (1)
PMID 34515338, PMID 27111235, PMID 28424162, PMID 29038338, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31141631, PMID 31648294, PMID 32499241, PMID 32967009, PMID 34110383, PMID 34196037, PMID 34666344, PMID 36287248, PMID 36631449, PMID 37774014, PMID 38836342, PMID 39161543, PMID 39333103, PMID 39863139, PMID 41678768, PMID 42389828
P30CA015704 (4), P30CA016672 (2), P30CA033572 (2), P50CA097274 (2), P50CA107399 (2), 2015 (1), 2025 (1), P01CA078902 (1), P30CA015083 (1), P30CA046934 (1), P30CA051008 (1), P30CA069533 (1), P30CA093373 (1), P50CA140158 (1), R01CA136551 (1)